Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin (ATSMAIN)
Protocol of Clinical Trial of EAFO 2012: Adjuvant Therapy of Skin Melanoma With Use of Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery. The study will also learn if different doses of alpha interferon work better than others.
The main questions it aims to answer are:
- Does alpha interferon help people with melanoma live longer without the cancer returning?
- Does a higher dose of alpha interferon work better than a lower dose?
- How does alpha interferon affect the immune system? Researchers will compare six different treatment approaches to see which one works best.
Participants will:
- Have surgery to remove their melanoma
- Receive one of six different treatments after surgery:
- Radiation therapy (40 Gy)
- Low-dose interferon (3 million IU)
- Surgery alone (no additional treatment)
- High-dose interferon (9 million IU/m² IV)
- Low-dose interferon with chemotherapy (dacarbazine + cisplatin)
- Chemotherapy alone (dacarbazine + cisplatin)
- Have regular check-ups to see if the cancer returns
- Have blood tests to check immune system function Key finding: The study will determine which treatment approach provides the best chance of survival without cancer recurrence.
研究概览
地位
详细说明
Study Rationale Cutaneous melanoma has a clinically meaningful risk of recurrence after complete surgical resection, particularly in higher-risk disease. Interferon alfa has historically been investigated as adjuvant immunotherapy in melanoma; randomized trials and meta-analyses have shown modest improvements in relapse-related endpoints with clinically important toxicity, and no consistent evidence that higher-dose strategies provide greater benefit than lower-dose strategies.
This study compared multiple adjuvant approaches used in local practice, including differing interferon dose intensities and combinations with cytotoxic chemotherapy or radiotherapy, to explore their comparative associations with recurrence and survival outcomes.
Study Design and Setting This was a single-country, comparative interventional study conducted after definitive surgery for cutaneous melanoma. Participants were allocated to one of six post-operative management groups based on clinical factors and treatment availability (non-randomized, open-label assignment).
Interventions (post-operative groups)
After surgical resection, participants received one of the following:
Adjuvant radiotherapy to the surgical bed: total dose 40 Gy.
Low-dose interferon alfa: 3 million IU subcutaneously on a scheduled regimen.
Observation / surgery alone (no adjuvant therapy).
Higher-dose interferon alfa: 9 million IU/m² intravenously on a scheduled regimen.
Low-dose interferon alfa + polychemotherapy: dacarbazine + cisplatin.
Polychemotherapy alone: dacarbazine + cisplatin. (Administration schedules, cycle lengths, and duration should be specified in the protocol or an accessible supporting document, consistent with protocol reporting standards.)
Assessments and Follow-up
Participants underwent baseline clinical evaluation after surgery and were followed at prespecified intervals for:
Disease status/recurrence surveillance (clinical assessments and imaging per local standard schedule).
Safety monitoring including treatment-emergent adverse events.
Immune monitoring via peripheral blood sampling with lymphocyte subset evaluation (including CD4/CD8 ratio) at baseline and predefined follow-up timepoints.
Outcomes (high-level; avoid duplicating Outcome Measures section) The study evaluated time-to-event and proportion-based clinical outcomes (recurrence and survival endpoints), safety/tolerability of each adjuvant approach, and longitudinal changes in immune markers.
Statistical Considerations (high-level) Time-to-event outcomes were planned for analysis using Kaplan-Meier methods with between-group comparisons using log-rank testing. Immune marker changes were planned for within- and between-group comparisons using parametric or nonparametric methods depending on distributional assumptions. A two-sided significance threshold of p < 0.05 was prespecified.
Limitations (protocol-relevant, non-results) Because treatment assignment was non-randomized, comparative estimates between groups are vulnerable to confounding by indication and selection bias. Interpretation of between-group differences therefore requires caution and may require adjustment methods (e.g., multivariable models/propensity approaches) if covariates were collected and sample size permits.
研究类型
注册 (实际的)
阶段
- 阶段2
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
• Histologically confirmed diagnosis of skin melanoma (stages I-IV according to TNM classification)
- Underwent complete surgical resection of primary tumor with negative margins
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy of at least 6 months
- Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L
- Adequate hepatic function: bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 2.5 × ULN
- Adequate renal function: creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min
- Willing and able to provide written informed consent
- Willing to comply with study procedures and follow-up schedule
Exclusion Criteria:
• Presence of distant metastases at the time of diagnosis (except for stage IV patients included per protocol)
- Prior immunotherapy, chemotherapy, or radiotherapy for melanoma
- History of other malignant neoplasms within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
- Severe or uncontrolled organ dysfunction (cardiac, hepatic, renal, pulmonary)
- Active infection requiring systemic therapy
- Known hypersensitivity to interferon-alpha or any study medications
- Known hypersensitivity to dacarbazine, cisplatin, or any excipients
- Pregnancy or breastfeeding
- Psychiatric or cognitive impairment that would interfere with study participation
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Surgery + Radiotherapy
Surgical resection of primary melanoma with wide excision (4-5 cm margin on trunk, 3 cm on head/neck) followed by adjuvant radiotherapy.
Radiation: external beam gamma therapy, 2 Gy daily fraction, total dose 40 Gy to primary site, 20 Gy to regional lymph node area.
Indicated for localized melanoma (T1-2N0M0) with Clark invasion level I-II.
n=49 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
External beam gamma radiotherapy delivered to primary melanoma site and regional lymph node area.
Regimen: 2 Gray (Gy) per fraction daily.
Total dose: 40 Gy to primary tumor site, 20 Gy to regional lymph node area.
Indicated only for localized melanoma with Clark invasion level I-II (T1-2N0M0).
Not recommended for deeper invasion (T3-4N0M0) as it may accelerate disease progression
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
|
|
实验性的:Surgery + Low-Dose IFN-α
Surgical resection followed by low-dose interferon alfa immunotherapy.
Regimen: 3 million IU intradermal daily until cumulative dose 30 million IU, then maintenance therapy (3 million IU single dose) administered only when CD4/CD8 ratio drops below 1.3.
Indicated for localized melanoma (T1-4N0M0) with low/intermediate metastasis risk.
n=38 patients
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
其他名称:
|
|
有源比较器:Surgery Alone (Control)
Surgical resection only, no adjuvant therapy.
Wide excision of primary melanoma with margins 4-5 cm on trunk, 3 cm on head/neck.
Regional lymphadenectomy performed if enlarged nodes present.
Indicated for localized melanoma (T1-4N0M0) with low/intermediate metastasis risk as control group.
n=64 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
|
|
实验性的:Surgery + High-Dose IFN-α
Surgical resection followed by high-dose interferon alfa immunotherapy.
Regimen: 9 million IU/m² intravenous every 2 days for a total of 4 doses.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
Treatment discontinued in 29.6% of patients due to severe adverse events (hepatotoxicity, nephrotoxicity, cardiotoxicity, flu-like syndrome, leukopenia).
n=37 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
其他名称:
|
|
实验性的:Surgery + Low-Dose IFN-α + Polychemotherapy
Surgical resection followed by sequential immunochemotherapy.
Phase 1: Low-dose interferon alfa 3 million IU intradermal daily to cumulative 30 million IU.
Phase 2: 6 cycles of polychemotherapy (every 21 days): dacarbazine 1400 mg IV + cisplatin 50 mg IV.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
n=47 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
其他名称:
Alkylating agent chemotherapy.
Administered intravenously at 1400 mg per cycle.
Used in combination with cisplatin for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Common adverse effects: nausea, vomiting, stomatitis, alopecia, short-term diarrhea.
其他名称:
Platinum-based chemotherapy agent.
Administered intravenously at 50 mg per cycle.
Used in combination with dacarbazine for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Adverse effects: nausea, vomiting, nephrotoxicity (managed with hydration), ototoxicity
其他名称:
|
|
有源比较器:Surgery + Polychemotherapy Alone (Control)
Surgical resection followed by adjuvant polychemotherapy alone (control group for locoregional melanoma).
Regimen: 6 cycles every 21 days of dacarbazine 1400 mg IV + cisplatin 50 mg IV.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
n=43 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
其他名称:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
其他名称:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
其他名称:
Alkylating agent chemotherapy.
Administered intravenously at 1400 mg per cycle.
Used in combination with cisplatin for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Common adverse effects: nausea, vomiting, stomatitis, alopecia, short-term diarrhea.
其他名称:
Platinum-based chemotherapy agent.
Administered intravenously at 50 mg per cycle.
Used in combination with dacarbazine for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Adverse effects: nausea, vomiting, nephrotoxicity (managed with hydration), ototoxicity
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recurrence-free survival
大体时间:Up to 5 years following surgical resection
|
Time from surgical resection to first documented recurrence of melanoma (local, regional, or distant) or death from any cause, whichever occurs first.
Assessed through clinical examination, imaging studies, and histopathological confirmation when applicable.
|
Up to 5 years following surgical resection
|
|
5-year overall survival
大体时间:5 years following surgical resection
|
Proportion of participants alive at 5 years following surgical resection.
Survival status assessed through clinical follow-up visits and medical records review.
|
5 years following surgical resection
|
|
Change in CD4/CD8 Ratio
大体时间:Baseline and at 6 months post-treatment
|
Change in the ratio of CD4-positive to CD8-positive T lymphocytes from baseline to post-treatment.
Measured by flow cytometry using peripheral blood samples.
Assesses immunologic response to interferon-alpha therapy.
|
Baseline and at 6 months post-treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of treatment-related adverse events
大体时间:Through treatment completion, up to 12 months
|
Proportion of participants experiencing treatment-related adverse events, including severity grading according to Common Terminology Criteria for Adverse Events (CTCAE).
Particular focus on toxicity leading to treatment discontinuation.
|
Through treatment completion, up to 12 months
|
|
Time to recurrence
大体时间:Up to 5 years following surgical resection
|
Time from surgical resection to first documented recurrence of melanoma, measured in months.
Participants without recurrence are censored at the date of last follow-up.
|
Up to 5 years following surgical resection
|
|
Disease-free survival
大体时间:Up to 5 years following surgical resection
|
Time from surgical resection to first recurrence, second primary melanoma, or death from any cause, whichever occurs first.
|
Up to 5 years following surgical resection
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 按部位分类的肿瘤
- 肿瘤
- 组织学类型的肿瘤
- 皮肤病
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 神经内分泌肿瘤
- 痣和黑色素瘤
- 皮肤肿瘤
- 皮肤和结缔组织疾病
- 黑色素瘤
- 肽
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- Azoles
- 细胞计数
- 细胞学技术
- 血液学检查
- 细胞生理现象
- 血液生理现象
- 循环和呼吸生理现象
- 白细胞计数
- 生物因素
- 三亚齐斯
- 咪唑
- 无机化学物质
- 氯化合物
- 氮化合物
- 化学技术,分析
- 细胞间信号肽和蛋白质
- 白金化合物
- 放疗
- 细胞分离
- 免疫学技术
- 细胞因子
- 合并方式疗法
- 干扰素类型I。
- 干扰素
- 血细胞计数
- 光度法
- 免疫测试
- 监测,生理
- 免疫系统现象
- 荧光法
- 发光测量
- 淋巴细胞计数
- 细胞光度测定法
- CD4 Lymphocyte Count
- 达卡巴嗪
- 顺铂
- 干扰素-α
- 放射疗法,辅助
- 流式细胞仪
- 免疫学监测
- CD4-CD8 Ratio
其他研究编号
- 5
- EAFO Protocol 2012 (其他标识符:EAFO)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.